Marian J Morrison Professor of Breast Cancer Research, Professor of Surgery, Biochemistry and Molecular Biology
Surgery and Cancer Center
Enhancing hormone therapy and chemotherapy sensitivity of breast cancer
My laboratory was the first to report constitutive activation of NF-κB in estrogen receptor negative breast cancer. The current focus is on genomic aspects of anti-estrogen resistance, mechanisms of organ-specific metastasis and heterogeneity in normal breast. These studies have resulted in three patents, another pending and establishment of a start-up company. For example, NF-kB inhibitor developed in the lab entered phase I clinical trial for leukemia. FOXA1 has been identified as a biomarker for estrogen receptor positive breast cancer. Several cell line resources have been developed in the lab, which are being used worldwide for drug discovery purpose.